Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 297,211 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 297,211 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $23.26, for a total value of $6,913,127.86. Following the sale, the director owned 2,962 shares of the company’s stock, valued at approximately $68,896.12. This represents a 99.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $23.83 on Thursday. Dyne Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $25.00. The stock’s fifty day moving average price is $19.00 and its 200 day moving average price is $18.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The company has a market cap of $3.94 billion, a price-to-earnings ratio of -7.40 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the previous year, the firm earned ($1.05) earnings per share. On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DYN. T. Rowe Price Investment Management Inc. lifted its position in Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after purchasing an additional 14,727,667 shares during the period. Vanguard Group Inc. raised its stake in shares of Dyne Therapeutics by 14.9% during the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after buying an additional 1,455,151 shares during the last quarter. State Street Corp raised its stake in shares of Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after buying an additional 1,423,828 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Dyne Therapeutics by 45.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after buying an additional 1,618,000 shares during the period. Finally, Orbis Allan Gray Ltd acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at about $93,926,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on DYN shares. TD Cowen assumed coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. Sanford C. Bernstein lifted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.